# Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

> **NCT00494442** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 58 (actual)

## Conditions studied

- Ovarian Neoplasm

## Interventions

- **DRUG:** KU-0059436 (AZD2281)(PARP inhibitor)
- **DRUG:** KU-0059436 (AZD2281)(PARP inhibitor)

## Key facts

- **NCT ID:** NCT00494442
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-11
- **Primary completion:** 2009-03-17
- **Final completion:** 2017-07-20
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2018-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494442, "Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00494442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*